Media

Conference

Safety & Recalls
Regulatory Updates
Drug Coverage
COPD
Cardiovascular
Obstetrics-Gynecology & Women's Health
Ophthalmology
Clinical Pharmacology
Pediatrics
Urology
Pharmacy
Idiopathic Pulmonary Fibrosis
Diabetes and Endocrinology
Allergy, Immunology, and ENT
Musculoskeletal/Rheumatology
Respiratory
Psychiatry and Behavioral Health
Dermatology
Oncology

Formulary Digital Edition October 2008

October 1, 2008

Article

Rational approaches to the treatment of mixed dyslipidemia; Focus on eltrombopag; Drug Watch: Agents in late-stage development for the treatment of hepatitis B and C virus infections

Related Content

FDA Approves Stelara Biosimilar, Selarsdi

April 18th 2024

Article

Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.

Most Cancer Drugs With Accelerated Approval Don’t Show Benefit

April 18th 2024

Article

Researchers were unable to find a significant benefit for patients for the majority of cancer medications given accelerated FDA approval.

FDA Approves GSK's BLA for 5-in-1 Meningococcal Vaccine

April 17th 2024

Article

The vaccine combines the antigenic components of its two meningococcal vaccines: Bexsero and Menveo. The action date is Feb. 14, 2025.

KFF: Some Medicaid Beneficiaries are Uninsured After Being Disenrolled

April 12th 2024

Article

More than half of those survey by KFF who were disenrolled from Medicaid said they put off needed medical care because of costs.

Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens

April 12th 2024

Article

Jeffrey Casberg, M.S., R.Ph., a senior vice president of clinical pharmacy at IPD Analytics LLC, a drug intelligence firm that advises payers and pharmaceutical companies, talks about how payers are thinking about weight-loss drugs.